Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 50%
Hold 6%
Sell 6%
Strong Sell 0%

Bulls say

Eli Lilly demonstrates strong growth potential supported by significant revenue increases across its key therapeutic areas, notably cardiometabolic solutions where revenues surged by 16.1% year-over-year in Q4. The electrophysiology segment also exhibited remarkable growth, achieving a 35% year-over-year increase, which aligns with industry forecasts of approximately 15% growth in the EP market through 2026. Furthermore, with neuromodulation revenues rising by 10% year-over-year, Eli Lilly's diverse product offerings and consistent market expansion underscore a favorable outlook for the company's financial performance.

Bears say

Eli Lilly's stock outlook is negatively impacted by a significant 18% decline in share price following a disappointing guidance for 2026 and underperformance in its electrophysiology (EP) segment that fell short of consensus expectations. The company's reliance on the favorable outcomes of the upcoming CHAMPION-AF study, along with potential slow uptake of its portfolio and high debt levels due to recent acquisitions, raises concerns about operational leverage and financial stability. Additionally, risks such as pricing pressures and disappointing performance of key products like tirzepatide further contribute to an uncertain and concerning financial outlook for Eli Lilly.

Eli Lilly (LLY) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 50% recommend Buy, 6% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 18 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,215, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,215, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.